International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1309-1315 , 1 August 2008

Protein Kinase A RI-α Predicts for Prostate Cancer Outcome: Analysis of Radiation Therapy Oncology Group Trial 86-10

  • Li-Yan Khor, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Kyounghwa Bae, Ph.D.

      Affiliations

    • Radiation Therapy Oncology Group, American College of Radiology, Philadelphia, PA
    • ,
  • Tahseen Al-Saleem, M.D.

      Affiliations

    • Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Elizabeth H. Hammond, M.D.

      Affiliations

    • Department of Pathology, LDS Hospital, Intermountain Health Care, Salt Lake City, UT
    • ,
  • David J. Grignon, M.D.

      Affiliations

    • Department of Pathology, Indiana University, Indianapolis, IN
    • ,
  • William T. Sause, M.D.

      Affiliations

    • Department of Radiation, LDS Hospital, Salt Lake City, UT
    • ,
  • Miljenko V. Pilepich, M.D.

      Affiliations

    • Department of Radiation Oncology, UCLA Medical Center, Los Angeles, CA
    • ,
  • Paul P. Okunieff, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY
    • ,
  • Howard M. Sandler, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Alan Pollack, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • Corresponding Author InformationReprint requests to: Alan Pollack, M.D., Ph.D., Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111. Tel: (215) 728-2940; Fax: (215) 728-2868

Received 11 October 2007 ,Accepted 6 December 2007.

References 

  1. Mellon PL, Clegg CH, Correll LA, et al. Regulation of transcription by cyclic AMP-dependent protein kinase. Proc Natl Acad Sci USA. 1989;86:4887–4891
  2. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: New approaches to therapy. Cancer Res. 1990;50:7093–7100
  3. Bradbury AW, Carter DC, Miller WR, et al. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer. 1994;69:738–742
  4. Miller WR, Hulme MJ, Cho-Chung YS, et al. Types of cyclic AMP binding proteins in human breast cancers. Eur J Cancer. 1993;29A:989–991
  5. Shi SS, He ZG, Shao K, et al. Relationship between overexpression of the RIalpha subunit of the cAMP-dependent protein kinase and clinicopathological features of lung cancer. Zhonghu Zhong Liu Za Zhi. 2004;26:547–550
  6. Yokozaki H, Budillon A, Tortora G, et al. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res. 1993;53:868–872
  7. Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res. 2000;6:4343–4350
  8. Agrawal S, Kandimalla ER, Yu D, et al. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002;21:65–72
  9. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  10. Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group protocol 8610. Cancer. 2005;104:962–967
  11. Khor LY, Desilvio M, Li R, et al. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;66:25–30
  12. Neary CL, Nesterova M, Cho YS, et al. Protein kinase A isoenzyme switching: Eliciting differential cAMP signaling and tumor reversion. Oncogene. 2004;23:8847–8856
  13. Khor LY, Bae K, Pollack A, et al. COX-2 expression predicts prostate-cancer outcome: Analysis of data from the RTOG 92-02 trial. Lancet Oncol. 2007;69:912–920
  14. Pollack A, Grignon DJ, Heydon KH, et al. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: An analysis of RTOG 8610. J Clin Oncol. 2003;21:1238–1248
  15. Chakravarti A, Heydon K, Wu CL, et al. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 86-10. J Clin Oncol. 2003;21:3328–3334
  16. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst. 1997;89:158–165
  17. Cox D. Regression models and life tables. J Royal Stat Soc. 1972;34:187–229
  18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
  19. Miller WR. Regulatory subunits of PKA and breast cancer. Ann NY Acad Sci. 2002;968:37–48
  20. Wang H, Hang J, Shi Z, et al. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: In vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002;21:73–80
  21. Tortora G, Bianco R, Damiano V, et al. Oral antisense that targets protein kinase A cooperates with Taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res. 2000;6:2506–2512
  22. Chin C, Bae JH, Kim MJ, et al. Radiosensitization by targeting radioresistance-related genes with protein kinase A inhibitor in radioresistant cancer cells. Exp Mol Med. 2005;37:608–618
  23. Tortora G, Ciardiello F. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann NY Acad Sci. 2003;1002:236–243
  24. Hannoun-Levi J, Hachem P, Mu Z, et al. Protein kinase a RI[alpha] antisense sensitization of radiation and androgen deprivation. Int J Radiat Oncol Biol Phys. 2004;60:S462–S463
  25. Roach M, Hanks GE, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  26. Tortora G, Pepe S, Bianco C, et al. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene. 1994;9:3233–3240
  27. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem. 1996;271:19900–19907
  28. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem. 1999;274:7777–7783
  29. Kim J, Jia L, Stallcup MR, et al. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol. 2005;34:107–118
  30. Kasbohm EA, Guo R, Yowell CW, et al. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem. 2005;280:11583–11589
  31. Shipley WU, Desilvio M, Pilepich MV, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;64:1162–1167

 Supported in part by Grants CA-006927, CA-101984-01, CA-21661, and CA-32115 from the National Cancer Institute and grants from Varian Medical Systems, Palo Alto, CA and the Pennsylvania Department of Health.

 The contents are solely the responsibility of the authors and do not necessarily represent the official views of the supporting organizations.

 Conflict of interest: none.

PII: S0360-3016(07)04709-8

doi: 10.1016/j.ijrobp.2007.12.010

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1309-1315 , 1 August 2008

Article Tools

* Image Usage & Resolution